Drugmakers ask FDA to approve another Alzheimer’s drug, similar to Aduhelm
Sep 29, 2021
Drugmakers Eisai and Biogen are putting the Food and Drug Administration to the test with a request to approve a second Alzheimer’s drug that works like aducanumab (Aduhelm), the new, yet controversial,...
Alzheimer’s drug slows mental, functional decline in Eli Lilly trial
Jan 12, 2021
Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.
Subtle cognitive problems may reveal Alzheimer’s far earlier than thought
Jan 01, 2020
Amyloid plaques accumulated faster in the brains of people who showed subtle difficulties in memory and learning tests.
Brain changes occur before amyloid plaques develop in those with Alzheimer’s, study finds
Dec 22, 2010
People who are considered at risk for developing Alzheimer’s have abnormal brain function even before they develop amyloid plaques, a study published in the Journal of Neuroscience found.